{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:38:52Z","timestamp":1759991932703,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2020\/12748-3","2019\/23864-7"],"award-info":[{"award-number":["2020\/12748-3","2019\/23864-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. National Institution of Health","award":["R01CA240257"],"award-info":[{"award-number":["R01CA240257"]}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Combination therapies or multi-targeted drugs have been pointed out as an option to prevent the emergence of resistant clones, which could make long-term treatment more effective and translate into better clinical outcomes for cancer patients. The NT157 compound is a synthetic tyrphostin that leads to long-term inhibition of IGF1R\/IRS1-2-, STAT3- and AXL-mediated signaling pathways. Given the importance of these signaling pathways for the development and progression of lung cancer, this disease becomes an interesting model for generating preclinical evidence on the cellular and molecular mechanisms underlying the antineoplastic activity of NT157. In lung cancer cells, exposure to NT157 decreased, in a dose-dependent manner, cell viability, clonogenicity, cell cycle progression and migration, and induced apoptosis (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In the molecular scenario, NT157 reduced expression of IRS1 and AXL and phosphorylation of p38 MAPK, AKT, and 4EBP1. Besides, NT157 decreased expression of oncogenes <jats:italic>BCL2, CCND1, MYB<\/jats:italic>, and <jats:italic>MYC<\/jats:italic> and increased genes related to cellular stress and apoptosis, <jats:italic>JUN, BBC3, CDKN1A, CDKN1B, FOS<\/jats:italic>, and <jats:italic>EGR1<\/jats:italic> (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), favoring a tumor-suppressive cell signaling network in the context of lung cancer. Of note, JNK was identified as a key kinase for NT157-induced IRS1 and IRS2 phosphorylation, revealing a novel axis involved in the mechanism of action of the drug. NT157 also presented potentiating effects on EGFR inhibitors in lung cancer cells. In conclusion, our preclinical findings highlight NT157 as a putative prototype of a multitarget drug that may contribute to the antineoplastic arsenal against lung cancer.<\/jats:p>","DOI":"10.1038\/s41598-022-21419-6","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T12:07:15Z","timestamp":1665576435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells"],"prefix":"10.1038","volume":"12","author":[{"given":"L\u00edvia Bassani Lins","family":"de Miranda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keli","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Luiz","family":"Coelho-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Traina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu S.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"21419_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus, A. et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Engl. J. Med. 376, 917\u2013927 (2017).","journal-title":"N. Engl. J. Med."},{"key":"21419_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong, L. et al. Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. Signal Transduct. Target Ther. 6, 201 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"21419_CR3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2174\/092986708783503212","volume":"15","author":"A Petrelli","year":"2008","unstructured":"Petrelli, A. & Giordano, S. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. Curr. Med. Chem. 15, 422\u2013432 (2008).","journal-title":"Curr. Med. Chem."},{"key":"21419_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","volume":"7","author":"RR Ramsay","year":"2018","unstructured":"Ramsay, R. R., Popovic-Nikolic, M. R., Nikolic, K., Uliassi, E. & Bolognesi, M. L. A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl. Med. 7, 3 (2018).","journal-title":"Clin. Transl. Med."},{"key":"21419_CR5","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1158\/1535-7163.MCT-13-0842","volume":"13","author":"N Ibuki","year":"2014","unstructured":"Ibuki, N. et al. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer. Mol. Cancer Ther. 13, 2827\u20132839 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"21419_CR6","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1158\/0008-5472.CAN-12-3385","volume":"73","author":"H Reuveni","year":"2013","unstructured":"Reuveni, H. et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res. 73, 4383\u20134394 (2013).","journal-title":"Cancer Res."},{"key":"21419_CR7","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/onc.2015.229","volume":"35","author":"E Flashner-Abramson","year":"2016","unstructured":"Flashner-Abramson, E. et al. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling. Oncogene 35, 2675\u20132680 (2016).","journal-title":"Oncogene"},{"key":"21419_CR8","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1038\/onc.2015.326","volume":"35","author":"E Sanchez-Lopez","year":"2016","unstructured":"Sanchez-Lopez, E. et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene 35, 2634\u20132644 (2016).","journal-title":"Oncogene"},{"key":"21419_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-019-0102-5","volume":"5","author":"BA Fenerich","year":"2020","unstructured":"Fenerich, B. A. et al. NT157 has antineoplastic effects and inhibits IRS1\/2 and STAT3\/5 in JAK2(V617F)-positive myeloproliferative neoplasm cells. Signal Transduct. Target Ther. 5, 5 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"21419_CR10","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1158\/1535-7163.MCT-17-0377","volume":"17","author":"SP Su","year":"2018","unstructured":"Su, S. P. et al. Impact of the anticancer drug NT157 on tyrosine kinase signaling networks. Mol. Cancer Ther. 17, 931\u2013942 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"21419_CR11","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1073\/pnas.1718414115","volume":"115","author":"H Xu","year":"2018","unstructured":"Xu, H. et al. Ablation of insulin receptor substrates 1 and 2 suppresses Kras-driven lung tumorigenesis. Proc. Natl. Acad. Sci. USA. 115, 4228\u20134233 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"21419_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1158\/2159-8290.CD-12-0446","volume":"3","author":"M Molina-Arcas","year":"2013","unstructured":"Molina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S. & Downward, J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. 3, 548\u2013563 (2013).","journal-title":"Cancer Discov."},{"key":"21419_CR13","first-page":"9","volume":"23","author":"F Nurwidya","year":"2016","unstructured":"Nurwidya, F., Andarini, S., Takahashi, F., Syahruddin, E. & Takahashi, K. Implications of insulin-like growth factor 1 receptor activation in lung cancer. Malays. J. Med. Sci. 23, 9\u201321 (2016).","journal-title":"Malays. J. Med. Sci."},{"key":"21419_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cllc.2011.10.006","volume":"13","author":"M Nakagawa","year":"2012","unstructured":"Nakagawa, M. et al. Clinical significance of IGF1R expression in non-small-cell lung cancer. Clin. Lung Cancer. 13, 136\u2013142 (2012).","journal-title":"Clin. Lung Cancer."},{"key":"21419_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220567","volume":"14","author":"AJ Piper","year":"2019","unstructured":"Piper, A. J. et al. Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC). PLoS ONE 14, e0220567 (2019).","journal-title":"PLoS ONE"},{"key":"21419_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4132\/jptm.2015.07.10","volume":"49","author":"E Park","year":"2015","unstructured":"Park, E. et al. Membranous insulin-like growth factor-1 receptor (IGF1R) expression is predictive of poor prognosis in patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. J. Pathol. Transl. Med. 49, 382\u2013388 (2015).","journal-title":"J. Pathol. Transl. Med."},{"key":"21419_CR17","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1016\/j.ijrobp.2011.06.1999","volume":"82","author":"Y Sun","year":"2012","unstructured":"Sun, Y. et al. Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 82, e563-572 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"21419_CR18","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/onc.2012.146","volume":"32","author":"M Cortes-Sempere","year":"2013","unstructured":"Cortes-Sempere, M. et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR\/Akt pathway in non-small cell lung cancer. Oncogene 32, 1274\u20131283 (2013).","journal-title":"Oncogene"},{"key":"21419_CR19","doi-asserted-by":"publisher","first-page":"8288","DOI":"10.1158\/1078-0432.CCR-05-0827","volume":"11","author":"EB Haura","year":"2005","unstructured":"Haura, E. B., Zheng, Z., Song, L., Cantor, A. & Bepler, G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin. Cancer Res. 11, 8288\u20138294 (2005).","journal-title":"Clin. Cancer Res."},{"key":"21419_CR20","volume":"3","author":"P Dutta","year":"2014","unstructured":"Dutta, P., Sabri, N., Li, J. & Li, W. X. Role of STAT3 in lung cancer. JAKSTAT. 3, e999503 (2014).","journal-title":"JAKSTAT."},{"issue":"Suppl 3","key":"21419_CR21","doi-asserted-by":"publisher","first-page":"S467","DOI":"10.1245\/s10434-012-2795-3","volume":"20","author":"M Ishikawa","year":"2013","unstructured":"Ishikawa, M. et al. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ann. Surg. Oncol. 20(Suppl 3), S467-476 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"21419_CR22","doi-asserted-by":"publisher","first-page":"17770","DOI":"10.1038\/s41598-017-18120-4","volume":"7","author":"K Iida","year":"2017","unstructured":"Iida, K. et al. Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL. Sci. Rep. 7, 17770 (2017).","journal-title":"Sci. Rep."},{"key":"21419_CR23","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/ng.2330","volume":"44","author":"Z Zhang","year":"2012","unstructured":"Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852\u2013860 (2012).","journal-title":"Nat. Genet."},{"key":"21419_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","volume":"10","author":"H Taniguchi","year":"2019","unstructured":"Taniguchi, H. et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat. Commun. 10, 259 (2019).","journal-title":"Nat. Commun."},{"key":"21419_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212\u2009Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"21419_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.04.030","volume":"456","author":"APN Rodrigues Alves","year":"2019","unstructured":"Rodrigues Alves, A. P. N. et al. IGF1R\/IRS1 targeting has cytotoxic activity and inhibits PI3K\/AKT\/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Lett. 456, 59\u201368 (2019).","journal-title":"Cancer Lett."},{"key":"21419_CR27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s10637-020-01028-8","volume":"39","author":"R Scopim-Ribeiro","year":"2021","unstructured":"Scopim-Ribeiro, R. et al. NT157, an IGF1R-IRS1\/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Invest. New Drugs. 39, 736\u2013746 (2021).","journal-title":"Invest. New Drugs."},{"key":"21419_CR28","doi-asserted-by":"publisher","first-page":"44332","DOI":"10.18632\/oncotarget.6293","volume":"6","author":"J Zhou","year":"2015","unstructured":"Zhou, J. et al. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer. Oncotarget 6, 44332\u201344345 (2015).","journal-title":"Oncotarget"},{"key":"21419_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12672-018-0343-8","volume":"9","author":"Y Yang","year":"2018","unstructured":"Yang, Y., Chan, J. Y., Temiz, N. A. & Yee, D. Insulin receptor substrate suppression by the tyrphostin NT157 inhibits responses to insulin-like growth factor-I and insulin in breast cancer cells. Horm. Cancer. 9, 371\u2013382 (2018).","journal-title":"Horm. Cancer."},{"key":"21419_CR30","first-page":"74","volume":"6","author":"C Garofalo","year":"2015","unstructured":"Garofalo, C. et al. Preclinical effectiveness of selective inhibitor of IRS-1\/2 NT157 in osteosarcoma cell lines. Front. Endocrinol. Lausanne. 6, 74 (2015).","journal-title":"Front. Endocrinol. Lausanne."},{"key":"21419_CR31","doi-asserted-by":"publisher","first-page":"153303382110279","DOI":"10.1177\/15330338211027916","volume":"20","author":"S Yu","year":"2021","unstructured":"Yu, S. et al. NT157 inhibits HCC migration via downregulating the STAT3\/Jab1 signaling pathway. Technol. Cancer Res. Treat. 20, 15330338211027916 (2021).","journal-title":"Technol. Cancer Res. Treat."},{"key":"21419_CR32","doi-asserted-by":"publisher","first-page":"e15467","DOI":"10.1097\/MD.0000000000015467","volume":"98","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Prognostic value of IGF-1R in lung cancer: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 98, e15467 (2019).","journal-title":"Medicine (Baltimore)"},{"key":"21419_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1478-811X-8-31","volume":"8","author":"GV Chaitanya","year":"2010","unstructured":"Chaitanya, G. V., Steven, A. J. & Babu, P. P. PARP-1 cleavage fragments: Signatures of cell-death proteases in neurodegeneration. Cell Commun. Signal. 8, 31 (2010).","journal-title":"Cell Commun. Signal."},{"key":"21419_CR34","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1093\/nar\/gkn550","volume":"36","author":"A Kinner","year":"2008","unstructured":"Kinner, A., Wu, W., Staudt, C. & Iliakis, G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 36, 5678\u20135694 (2008).","journal-title":"Nucleic Acids Res."},{"key":"21419_CR35","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1038\/s41467-020-18442-4","volume":"11","author":"R Wang","year":"2020","unstructured":"Wang, R. et al. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nat. Commun. 11, 4607 (2020).","journal-title":"Nat. Commun."},{"key":"21419_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/bjc.2016.428","volume":"116","author":"CM Gay","year":"2017","unstructured":"Gay, C. M., Balaji, K. & Byers, L. A. Giving AXL the axe: Targeting AXL in human malignancy. Br. J. Cancer. 116, 415\u2013423 (2017).","journal-title":"Br. J. Cancer."},{"key":"21419_CR37","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1074\/jbc.M101521200","volume":"277","author":"V Aguirre","year":"2002","unstructured":"Aguirre, V. et al. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 277, 1531\u20131537 (2002).","journal-title":"J. Biol. Chem."},{"key":"21419_CR38","doi-asserted-by":"publisher","first-page":"26702","DOI":"10.18632\/oncotarget.15804","volume":"8","author":"Y Fang","year":"2017","unstructured":"Fang, Y. et al. Inactivation of p38 MAPK contributes to stem cell-like properties of non-small cell lung cancer. Oncotarget 8, 26702\u201326717 (2017).","journal-title":"Oncotarget"},{"key":"21419_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1165\/ajrcmb.26.5.4689","volume":"26","author":"AK Greenberg","year":"2002","unstructured":"Greenberg, A. K. et al. Selective p38 activation in human non-small cell lung cancer. Am. J. Respir. Cell Mol. Biol. 26, 558\u2013564 (2002).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"21419_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2217\/lmt.13.72","volume":"3","author":"H Cheng","year":"2014","unstructured":"Cheng, H. et al. Targeting the PI3K\/AKT\/mTOR pathway: Potential for lung cancer treatment. Lung Cancer Manag. 3, 67\u201375 (2014).","journal-title":"Lung Cancer Manag."},{"key":"21419_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/15384101.2016.1151581","volume":"15","author":"X Qin","year":"2016","unstructured":"Qin, X., Jiang, B. & Zhang, Y. 4E-BP1, a multifactor regulated multifunctional protein. Cell Cycle 15, 781\u2013786 (2016).","journal-title":"Cell Cycle"},{"key":"21419_CR42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1046\/j.1365-2443.1998.00223.x","volume":"3","author":"Y Tsujimoto","year":"1998","unstructured":"Tsujimoto, Y. Role of Bcl-2 family proteins in apoptosis: Apoptosomes or mitochondria?. Genes Cells. 3, 697\u2013707 (1998).","journal-title":"Genes Cells."},{"key":"21419_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199688","volume":"13","author":"J Xu","year":"2018","unstructured":"Xu, J. & Lin, D. I. Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas. PLoS ONE 13, e0199688 (2018).","journal-title":"PLoS ONE"},{"key":"21419_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41389-021-00309-y","volume":"10","author":"Y Ciciro","year":"2021","unstructured":"Ciciro, Y. & Sala, A. MYB oncoproteins: Emerging players and potential therapeutic targets in human cancer. Oncogenesis. 10, 19 (2021).","journal-title":"Oncogenesis."},{"key":"21419_CR45","doi-asserted-by":"publisher","first-page":"609","DOI":"10.21873\/anticanres.13990","volume":"40","author":"P Chanvorachote","year":"2020","unstructured":"Chanvorachote, P., Sriratanasak, N. & Nonpanya, N. C-myc contributes to malignancy of lung cancer: A potential anticancer drug target. Anticancer Res. 40, 609\u2013618 (2020).","journal-title":"Anticancer Res."},{"key":"21419_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1128\/MCB.16.1.211","volume":"16","author":"GA Preston","year":"1996","unstructured":"Preston, G. A. et al. Induction of apoptosis by c-Fos protein. Mol. Cell Biol. 16, 211\u2013218 (1996).","journal-title":"Mol. Cell Biol."},{"key":"21419_CR47","doi-asserted-by":"publisher","first-page":"11318","DOI":"10.1073\/pnas.201208798","volume":"98","author":"J Han","year":"2001","unstructured":"Han, J. et al. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc. Natl. Acad. Sci. USA. 98, 11318\u201311323 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"21419_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00204-014-1430-4","volume":"89","author":"I Dutto","year":"2015","unstructured":"Dutto, I., Tillhon, M., Cazzalini, O., Stivala, L. A. & Prosperi, E. Biology of the cell cycle inhibitor p21(CDKN1A): Molecular mechanisms and relevance in chemical toxicology. Arch Toxicol. 89, 155\u2013178 (2015).","journal-title":"Arch Toxicol."},{"key":"21419_CR49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3389\/fendo.2018.00393","volume":"9","author":"M Cusan","year":"2018","unstructured":"Cusan, M. et al. Landscape of CDKN1B mutations in luminal breast cancer and other hormone-driven human tumors. Front. Endocrinol. Lausanne. 9, 393 (2018).","journal-title":"Front. Endocrinol. Lausanne."},{"key":"21419_CR50","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1038\/srep05416","volume":"4","author":"H Zhang","year":"2014","unstructured":"Zhang, H. et al. EGR1 decreases the malignancy of human non-small cell lung carcinoma by regulating KRT18 expression. Sci. Rep. 4, 5416 (2014).","journal-title":"Sci. Rep."},{"key":"21419_CR51","doi-asserted-by":"publisher","first-page":"566","DOI":"10.2174\/156800909788486759","volume":"9","author":"Y Yu","year":"2009","unstructured":"Yu, Y., Wan, Y. & Huang, C. The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target. Curr. Cancer Drug Targets. 9, 566\u2013571 (2009).","journal-title":"Curr. Cancer Drug Targets."},{"key":"21419_CR52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2015.00024","volume":"5","author":"M Milella","year":"2015","unstructured":"Milella, M. et al. PTEN: Multiple functions in human malignant tumors. Front. Oncol. 5, 24 (2015).","journal-title":"Front. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21419-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21419-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21419-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T13:32:34Z","timestamp":1665581554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21419-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21419"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21419-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.S.K. has research grants from Taiho Pharmaceutical, Johnson & Johnson, MiRXES, and MiNA therapeutics. The other authors declare that there is no conflict of interest regarding the publication of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17092"}}